Set for a global launch this month across 40 countries, Eucerin’s triple protect serum and SPF 30 protective fluid would sit as part of the brand’s acne-prone skin series Dermopure, with both designed to “reduce and prevent” post-acne marks and blemishes and control shine.
The triple effect serum contained Beiersdorf’s patented ingredient Thiamidol, used to counteract and reverse hyperpigmentation by targeting melanin formation in the skin. It also contained salicylic acid to reduce blemishes and licochalcone A to prevent new blemishes appearing, along with sebum-regulation technology for a “long-lasting matte look”. The SPF 30 fluid combined UV filters with antibacterial decanediol to help prevent blemishes and licochalcone A to soothe irritated skin. The formulation also featured Beiersdorf’s sebum-regulation technology.
Beiersdorf said the products had “enhanced efficiency when used in combination”.
Post-acne marks a ‘completely new market’ with high consumer demand
Cornelius Becker, global head of derma at Beiersdorf, said its patented ingredient Thiamidol had already enabled the company to fast advance in the even skin segment and would now take it into new territory.
“Now, for the first time, we were able to bring Thiamidol into the acne category, thus continuing the success story of our life-changing ingredient also for blemish-prone skin,” Becker said.
Patrick Rasquinet, executive board member for pharmacy and selective brands at Beiersdorf, said targeting post-acne marks certainly edged Beiersdorf into a “completely new market”.
“The skin condition affects large numbers of people worldwide, with a severe impact on their psychological wellbeing. Our effective dermocosmetic solutions offer great potential to meet the correspondingly high demand of our consumers,” Rasquinet said.
And it was this focus, he said – on the emotional and self-esteem side of post-acne marks – that had driven Beiersdorf into this space.
Three-year product development and clinical studies
Speaking to CosmeticsDesign-Europe, a spokeswoman for Beiersdorf said the two Dermopure products had taken three years to develop, off the back of the ten years of research dedicated to refining its Thiamidol ingredient.
The products had also undergone a 12-week clinical study to test efficacy that showed visible results after just two weeks of use, along with an eight-week study investigating combined-use efficacy which demonstrated “enhanced efficacy when used in combination”.
Full study findings would be published in a symposium at the European Academy of Dermatology and Venerology (EADV) Congress 2021, she said.
